Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Corcept Therapeutics Incorporated - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CORT
Nasdaq
2830
www.corcept.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Corcept Therapeutics Incorporated
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
- Feb 12th, 2025 9:05 pm
3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth
- Feb 5th, 2025 11:01 am
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
- Feb 3rd, 2025 9:09 am
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
- Jan 31st, 2025 1:38 pm
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
- Jan 31st, 2025 1:03 pm
Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham
- Jan 30th, 2025 1:21 pm
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
- Jan 29th, 2025 5:00 pm
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
- Jan 29th, 2025 11:33 am
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Jan 24th, 2025 5:45 pm
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
- Jan 24th, 2025 2:15 pm
Medical Stock Soars To Highs As Cortisol Screening Grows
- Jan 22nd, 2025 4:35 pm
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)
- Jan 20th, 2025 11:53 pm
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?
- Jan 18th, 2025 6:59 pm
Discover 3 US Growth Stocks With Strong Insider Ownership
- Jan 7th, 2025 3:06 pm
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance
- Jan 7th, 2025 1:04 pm
Corcept Submits Application for Another Cushing's Syndrome Drug
- Dec 31st, 2024 6:40 pm
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
- Dec 30th, 2024 10:15 pm
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?
- Dec 25th, 2024 4:13 am
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial
- Dec 17th, 2024 10:16 am
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
- Dec 16th, 2024 1:00 pm
Scroll